title: [Organ and function preservation in prostate cancer].
abstract: BACKGROUND
  Curative treatment for prostate cancer is associated with risks which may adversely influence quality of life. Furthermore, there is a considerable rate of overdiagnosis of tumors which would be non-life-threatening if left untreated. Efforts have been made to reduce overtreatment.
  
  
  CONCLUSIONS
  Beside the traditional conservative symptomatic management especially in elderly patients with meaningful comorbidity, several prostate-sparing or deferred treatment options are currently discussed. For all of them, insufficient data on efficacy and safety are available.
  
  
  RESULTS
  Because of the required long-term follow-up of large sample sizes, conclusive data will not become available in the near future. Therefore, these treatment options have to be considered experimental to a large degree. This applies both to focally ablative techniques and to active surveillance of prostate cancer in patients with a long further life expectancy. Only in carefully selected patients with favorable tumor-associated risk profiles and high risk of medium-term competing mortality may active surveillance be considered a valid and relatively safe treatment option.
authors.affiliation: Klinik und Poliklinik für Urologie, Universitätsklinikum "Carl Gustav Carus" der Technischen Universität Dresden, Fetscherstraße 74, 01307, Dresden, Deutschland, Michael.Froehner@uniklinikum-dresden.de.
authors.forename: M
authors.initials: M
authors.lastname: Fröhner
authors.forename: M
authors.initials: M
authors.lastname: Wirth
mesh_terms: D006801:Humans; D008297:Male; D019060:Minimally Invasive Surgical Procedures / Q000379:methods; D059351:Organ Sparing Treatments / Q000379:methods*; D058958:Organs at Risk / Q000528:radiation effects / Q000601:surgery*; D011468:Prostatectomy / Q000379:methods*; D011471:Prostatic Neoplasms / Q000175:diagnosis / Q000532:radiotherapy* / Q000601:surgery*; D020127:Recovery of Function; D057832:Watchful Waiting / Q000379:methods*
references.citation: N Engl J Med. 2014 Mar 6;370(10):932-42
references.pmid: 24597866
references.citation: N Engl J Med. 2012 Jul 19;367(3):203-13
references.pmid: 22808955
references.citation: Curr Opin Urol. 2014 May;24(3):209-17
references.pmid: 24670871
references.citation: Curr Opin Urol. 2014 May;24(3):231-5
references.pmid: 24637315
references.citation: Curr Opin Urol. 2014 May;24(3):236-40
references.pmid: 24625427
references.citation: N Engl J Med. 2013 Jan 31;368(5):436-45
references.pmid: 23363497
references.citation: Eur Urol. 2011 Sep;60(3):554-63
references.pmid: 21664039
references.citation: Eur Urol. 2013 Mar;63(3):428-35
references.pmid: 23084329
references.citation: Eur Urol. 2013 Dec;64(6):981-7
references.pmid: 23473579
references.citation: Urol Oncol. 2014 Aug;32(6):912-23
references.pmid: 24411788
references.citation: Curr Opin Urol. 2014 May;24(3):218-24
references.pmid: 24637316
references.citation: N Engl J Med. 2002 Sep 12;347(11):790-6
references.pmid: 12226149
references.citation: Technol Cancer Res Treat. 2003 Feb;2(1):25-30
references.pmid: 12625751
references.citation: Drugs Aging. 2013 Dec;30(12):959-67
references.pmid: 24097331